Markets

Global Minimal Residual Disease Testing Market Report 2022:

Dublin, Dec. 26, 2022 (GLOBE NEWSWIRE) — “Minimum Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User (Hospitals, Specialty Clinics, Diagnostic Laboratories, research and academic institutes) and region – Global Forecast to 2027.” the report was added to ResearchAndMarkets.com’s offering.

The global minimal residual disease testing market is valued at USD 1.2 billion in 2022 and is projected to reach USD 2.3 billion by 2027, at a CAGR of 14.0% during the forecast period. The growth of the market is driven by the increase in the number of patients with cancer and hematological malignancies, the growing awareness of governments about cancer, and the increasing collaboration and partnership between companies.

The PCR segment had the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment had the highest growth rate in the minimal residual disease testing market. Ease of use, easy availability of assay kits and good sensitivity are the main factors contributing to the large share of this segment.

The hematologic malignancies application segment had the highest CAGR

On the basis of application, the minimal residual disease testing market is segmented into hematologic malignancies, solid tumors, and other applications. In 2021, the hematological malignancy application segment had the largest share. Factors contributing to the growth of this segment are the increase in the incidence of leukemia, lymphoma and their types and the awareness of continuous monitoring of patients with these diseases.

Asia Pacific: Fastest Growing Market for Minimal Residual Disease Testing

The global minimal residual disease testing market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Asia Pacific is projected to register the highest CAGR during the forecast period.

Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, presence of large patient population, increasing focus of key players in the region, government efforts to increase awareness of disease detection, continuously rising health care costs, an increasing number of hospitals and clinical diagnostic laboratories in India and China, and a strengthening research base for diagnostic procedures across India, China and Japan.

Report Attributes Details
Number of pages 175
Forecast period 2022 – 2027
Estimated market value (USD) in 2022 1.2 billion dollars
Projected Market Value (USD) to 2027 2.3 billion dollars
Compound annual growth rate 14.0%
Regions Covered Global

List of companies profiled in the report:

  • Labcorp Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Guardant Health (USA)
  • Sismek Corporation (Japan)
  • NeoGenomics Laboratories, Inc. (USA)
  • Adaptive Biotechnologies Corporation (USA)
  • ArcherDX, Inc. (USA)
  • Asuragen Inc. (USA)
  • Arup Laboratories Inc. (USA)
  • Bio-Rad Laboratories, Inc. (USA)
  • Cergentis BV (Netherlands)
  • Molecular MD (ICON plc) (Ireland)
  • Invivoscribe, Inc. (USA)
  • Mission Bio, Inc. (USA)
  • Natera, Inc. (USA)
  • Opko Health, Inc. (USA)
  • Quest Diagnostics (USA)
  • Genetron Health (China)

Key topics covered:

1. Presentation

2 Research methodology

3 Summary

4 Premium Insights

5 Market overview

6 Minimal Residual Disease Testing Market, by Technology
6.1 Introduction
6.2 Flow cytometry
6.3 Polymerase chain reaction
6.4 Next Generation Sequencing
6.5 Other Technologies

7 Minimal Residual Disease Testing Market, by Application
7.1 Introduction
7.2 Hematological malignancy
7.2.1 Leukemia
7.2.1.1 Myeloid leukemia
7.2.1.2 Lymphoblastic leukemia
7.2.1.3 Other leukemias
7.2.2 Lymphoma
7.2.2.1 Non-Hodgkin’s lymphoma (Nhl)
7.2.2.2 Hodgkin’s lymphoma
7.3 Solid tumor
7.4 Other Applications

8 Minimal Residual Disease Testing Market, by End User
8.1 Introduction
8.2 Hospitals and special clinics
8.3 Diagnostic laboratories
8.4 Academic and research institutes
8.5 Other End Users

9 Minimal Residual Disease Testing Market, by Region

10 The competitive landscape

11 Company profile

12 Appendix

For more information on this report, visit https://vvv.researchandmarkets.com/r/1pv18v

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

  • Minimal Residual Disease (MRD) Testing Market.


        

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button